Locus 101: ABCC4 (13q32.1)
| Meta-analysis summary statistics for associations meeting genome-wide significance |
| Lead SNP | Biochemicals | EA/OA | Ntotal | EAF | Effect (SE) | Pmeta | Details |
| rs8002180 |
X-12244--N-acetylcarnosine |
T/C |
6279 |
0.72 |
-0.024 (0.002) |
8.23·10-23 |
show |
EA = effect allele; OA = other allele; EAF = frequency of effect allele;
| Summary of biological annotations |
| SNP | rs8002180 |
| Chromosomal location | Chr13: 94,720,766 (13q32.1) |
| Gene (distance) | ABCC4 (0) |
| Predicted causal gene | unknown |
| Gene/protein classification | transporter |
| Metabolite (Pathway) | X-12244--N-acetylcarnosine (Dipeptide; Peptide) |
| Biochemical locus-metabolite relationship | X-12244 has been identified as N-acetylcarnosine |
| eQTL associations | - |
| Medical information |
| Complex trait associations | - |
| Known metabolite associations | - |
| Inborn error of metabolism | - |
| Pharmacological information |
| ChEMBL ID | CHEMBL1743128 |
| Drug information |
Substrates: Adefovir, tenofovir, cyclic AMP, dehydroepian- drosterone sulphate, methotrexate, topotecan, furosemide, cyclic GMP, bile acids plus glutathione. Inhibitors: Celecoxib, diclofenac (PMID: 20190787)
|
| Locus information for top associated metabolite |
HapMap2 imputation | 1KGP imputation |

